Accuracy of ICD Influenza Discharge Diagnosis Codes in Hospitalized Adults From the Valencia Region, Spain, in the Pre-COVID-19 Period 2012/2013 to 2017/2018
Autors de IIS La Fe
Autors aliens a IIS La Fe
- Mira-Iglesias, Ainara
- Lopez-Lacort, Monica
- Bricout, Helene
- Loiacono, Matthew
- Carballido-Fernandez, Mario
- Mollar-Maseres, Joan
- Schwarz-Chavarri, German
- Lopez-Labrador, F. Xavier
- Puig-Barbera, Joan
- Diez-Domingo, Javier
- Orrico-Sanchez, Alejandro
Grups d'Investigació
Abstract
BackgroundInternational Classification of Diseases (ICD) codes obtained from real-world data can be used to identify influenza cases for epidemiological research but, without validation, may introduce biases. The objective of this study was to validate ICD influenza discharge diagnoses using real-time reverse transcription-polymerase chain reaction (RT-PCR) laboratory-confirmed influenza (LCI) results.MethodsThe study was conducted during six influenza seasons (2012/2013-2017/2018) in the Valencia Hospital Surveillance Network for the Study of Influenza (VAHNSI). Patients aged 18+ years were identified via active-surveillance and had to meet an influenza-like illness (ILI) case definition to be included. All patients were tested for influenza by real-time RT-PCR. Main and secondary influenza discharge diagnosis codes were extracted from hospital discharge letters. Positive predictive values (PPVs) and the complementary of the sensitivities (1-Sensitivity) of ICD codes with corresponding 95% credible intervals (CrIs) were estimated via binomial Bayesian regression models.ResultsA total of 13,545 patients were included, with 2257 (17%) positive for influenza. Of 2257 LCI cases, 1385 (61%) were not ICD-coded as influenza. Overall, 74.73% (95% CrI: 63.24-84.44) of LCI were not-ICD coded as influenza (1-Sensitivity) after adjustment. Sensitivity improved across seasons and with increasing age. Average PPV was 74.02% (95% CrI: 68.58-79.17), ranging from 43.71% to 81.57% between seasons.ConclusionUsing only main and secondary discharge diagnosis codes for influenza detection markedly underestimates the full burden of influenza in hospitalized patients. Future studies, including post-COVID context, using prospective surveillance for ILI are required to assess the validity of hospital discharge data as a tool for determining influenza-related burden of disease.
Dades de la publicació
- ISSN/ISSNe:
- 1750-2640, 1750-2659
- Tipus:
- Article
- Pàgines:
- -
- DOI:
- 10.1111/irv.70069
- PubMed:
- 39909969
- Factor d'Impacte:
- 1,637 SCImago ℠
- Quartil:
- Q1 SCImago ℠
INFLUENZA AND OTHER RESPIRATORY VIRUSES Blackwell Publishing Inc.
Documents
- No hi ha documents
Filiacions
Filiacions no disponibles
Projectes associats
Identificación de biomarcadores inmunológicos en pacientes alérgicos.
Investigador Principal: MIGUEL TORTAJADA GIRBÉS
LET-INM-2020 . 2023
Ensayo clínico de eficacia y seguridad, prospectivo, multicéntrico, aleatorizado, doble ciego controlado con placebo, con inmunoterapia subcutánea en pacientes con rinitis/rinoconjuntivitis con o sin asma de leve a moderada sensibilizados a Dermatophagoides pteronyssinus y/o Dermatophagoides farinae.
Investigador Principal: MIGUEL TORTAJADA GIRBÉS
MM09-SIT-023 . 2023
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA).
Investigador Principal: MIGUEL TORTAJADA GIRBÉS
D3250C00024 . 2023
Evaluación de la eficacia y seguridad de la inmunoterapia subcutánea (Beltavac®) con extracto alergénico polimerizado de mezcla de ácaros del polvo en pacientes con rinitis/rinoconjuntivitis alérgica.
Investigador Principal: MIGUEL TORTAJADA GIRBÉS
2023
Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad a largo plazo de dupilumab en niños de 2 a <6 años con asma no controlada y/o sibilancias asmáticas graves recurrentes.
Investigador Principal: MIGUEL TORTAJADA GIRBÉS
EFC14771 . 2024
Estudio fase III multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo de la eficacia y la seguridad de tezepelumab en niños de 5 a <12 años con asma grave no controlada (HORIZON).
Investigador Principal: MIGUEL TORTAJADA GIRBÉS
D5180C00016 . 2024
Estudio epidemiológico de las enfermedades alérgicas pediátricas en España.
Investigador Principal: MIGUEL TORTAJADA GIRBÉS
ALERGOPEDIÁTRICA 2020 . 2024